Target species
Cats.
Indications for use, specifying the target species
Local anaesthesia of the laryngeal mucosa of the cat in order to facilitate endotracheal intubation by preventing the stimulation of the laryngeal reflex.
Contraindications
Do not use in animals which are hypovolaemic or show heart block. Do not use in known cases of hypersensitivity to the active substance or any of the excipients.
Special warnings
Laryngeal spasm can also be stimulated by removal of the endotracheal tube. This should be carried out while the patient is still under anaesthesia.
Special precautions for use
Special precautions for safe use in the target species:
Use with care in cases with hepatic and or cardiac insufficiency.
It is advisable to cold sterilise the nozzle between uses to avoid the spread of infection.
Special precautions to be taken by the person administering the veterinary medicinal product to animals
Lidocaine and chlorocresol may cause hypersensitivity (allergic) reactions. People with known hypersensitivity to these substances should avoid contact with the veterinary medicinal product.
Accidental exposure to the veterinary medicinal product may lead to local effects such as numbing, and systemic effects, such as dizziness or drowsiness. Accidental exposure, particularly oral, eye and inhalation exposure, should be avoided.
Personal protective equipment consisting of gloves should be worn when handling the veterinary medicinal product. Wash any exposed areas after use. If accidental exposure to eyes occurs, rinse with water.
In cases of severe or extended reactions, seek medical advice immediately and show the package leaflet or the label to the physician.
Lidocaine can form genotoxic and mutagenic metabolites in humans. These metabolites can also induce, in long-term toxicology studies in rats, carcinogenic effects at high doses.
Special precautions for the protection of the environment:
Not applicable.
Adverse reactions
None known.
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.
Use during pregnancy, lactation or lay
The safety of the veterinary medicinal product has not been established during pregnancy.
Pregnancy and lactation:
Use only according to the benefit-risk assessment by the responsible veterinarian.
Laboratory studies in mice have shown evidence of foetotoxic effects at high doses.
Interaction with other medicinal products and other forms of interaction
None known.
Administration route and dosage
For laryngopharyngeral use.
Give one or two sprays at the back of the throat.
Prior to use, prime the pump until liquid is released. Minimum of 4 sprays are recommended for priming the bottle before first use and at least 2 sprays are recommended for re-priming if unused for 7 days or longer.
Each spray (approximately 0.14 ml) contains approximately 2.8 mg of lidocaine hydrochloride monohydrate, which corresponds to 2.27 mg of lidocaine.
Allow 30-90 seconds before attempting intubation, so that the larynx is relaxed.
It should be noted that when removing the actuator from the spray pump it should be done vertically and not at an angle to ensure the pin does not get damaged.
Symptoms of overdose (and where applicable, emergency procedures and antidotes)
Maintain a patent airway and support ventilation with oxygen.
Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance
Not applicable.
Withdrawal period(s)
Not applicable.